Elevance Health, which is the parent company of Blue Cross and Blue Shield Health insurance plans in 14 states, has formed a strategic partnership with private equity company Clayton, Dubilier & Rice (CD&R). The deal is expected to "advance primary care delivery" with stronger patient-provider relationships, care coordination and integrated health coaching.
The insurance giant and CD&R will bring together certain segments of Elevance's Carelon Health division and the PE firm's portfolio companies apree health and Millennium Physician Group, according to the announcement issued Monday. The new joint primary care model will seek to address each patient's physical, social and behavioral health through a whole-person approach, the partners said.
The strategic partnership's advanced primary care models take a whole health approach to address the physical, social, and behavioral health of every person. The foundation of the new advanced primary care offering will be stronger patient-provider relationships supported by data-driven insights, care coordination and referral management, and integrated health coaching. It will also leverage realigned incentives through value-based care agreements that enable care providers, assist individuals in leading healthier lives, and make care more affordable.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.